Psmb10 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Full Name | Proteasome Subunit Beta Type-10 |
|---|---|
| Gene | [PSMB10](/genes/psmb10) |
| UniProt ID | [P40306](https://www.uniprot.org/uniprot/P40306) |
| PDB ID | [5VFP](https://www.ebi.ac.uk/pdbe/5VFP) |
| Molecular Weight | 28.9 kDa |
| EC Number | 3.4.25.1 |
| Subcellular Localization | Cytoplasm, Nucleus |
| Protein Family | Proteasome beta subunit family |
| Aliases | LMP10, LMP7, ME10 |
PSMB10 (Proteasome Subunit Beta Type-10), also known as LMP10 (Low Molecular Mass Polypeptide 10), is a catalytic subunit of the immunoproteasome[1]. It provides chymotrypsin-like proteolytic activity and is primarily expressed in immune cells where it plays a crucial role in antigen processing and presentation. PSMB10 can also be expressed in neurons under certain stress conditions[2].
The immunoproteasome is an inducible form of the proteasome that contains alternative catalytic subunits (PSMB8/LMP7, PSMB9/LMP2, PSMB10/LMP10) that replace their constitutive counterparts in the 20S core particle. This generates peptides with different cleavage preferences, optimized for MHC class I antigen presentation[3].
PSMB10 shares the classic β-subunit fold:
In the immunoproteasome:
PSMB10 provides chymotrypsin-like activity:
The study of Psmb10 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Groettrup M, et al. The immunoproteasome in antigen processing and other immune functions. Nat Rev Immunol. 2021. ↩︎
Ferrington DA, et al. Altered proteasome in neurodegenerative disease. J Neurochem. 2020. ↩︎
Kim HM, et al. Immunoproteasome structure and function. Mol Immunol. 2022. ↩︎
Liu Y, et al. Targeting immunoproteasome for neurodegenerative diseases. Trends Pharmacol Sci. 2023. ↩︎